Trial
NCT02203474
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Chronic Obstructive Pulmonary Disease
Intervention
Tiotropium HFA BAI 5 mcg
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09